Detail of "70-51-9"

Reference

Effect of dose, time, and ascorbate on iron excretion after subcutaneous desferrioxamine

Effect of dose, time, and ascorbate on iron excretion after subcutaneous desferrioxamine. Hussain, M. A. M.; Flynn, D. M.; Green, N.; Hoffbrand, A. V. (Dep. Paediatr., R. Free Hosp., London, Engl.). Lancet, 8019, 977-9 (English) 1977. CODEN: LANCAO. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacodynamics) The effect of 12 and 24 h continuous s.c. infusion of desferrioxamine (D.F.) [70-51-9] on urinary Fe excretion was compared in 13 patients with b-thalassemia major and 1 with congenital sideroblastic anemia, all of whom were receiving regular blood-transfusions. D. F. (750 mg) given over a 12 h period, gave a mean total (30 h) Fe excretion of 17.5 mg, which was not different from the mean Fe excretion of 21.5 mg when the same dose was delivered over 24 h. D. F. (1500 mg) gave a mean urinary Fe excretion of 28.1 mg with a 12 h infusion, which was significantly less than the mean Fe excretion of 39.6 mg with 24 h infusion. The 1500 mg dose gave an increase in Fe excretion compared with the 750 mg dose when given by either 12 h or 24 h infusion. Seven of 8 patients, given D.F. over a 12 h period, had increased Fe excretion when thedose was increased from 750 to 2000 mg. When the dose was increased to 4000 mg, however, the effect on Fe excretion was variable. On the other hand, ascorbic-acid [50-81-7] therapy was invariably assocd. with increased Fe excretion after s.c. D.F. In 12 patients studied at different doselevels of D.F., ascorbate therapy was assocd. with increased Fe excretion ranging from 24 to 24.5%. Thus, in most patients with transfusional iron overload, s.c. D.F. over a 12 h period, at a dose ranging from 2 to 4 g daily with ascorbic-acid satn., is at present the most satisfactory method of removing excess iron.

Pharmacokinetics of the iron chelator desferrioxamine as affected by liposome encapsulation: potential in treatment of chronic hemosiderosis

Pharmacokinetics of the iron chelator desferrioxamine as affected by liposome encapsulation: potential in treatment of chronic hemosiderosis. Guilmette, R. A.; Cerny, E. A.; Rahman, Y. E. (Div. Biol. Med. Res., Argonne Natl. Lab., Argonne, Ill., USA). Life Sci., 22(4), 313-19 (English) 1978. CODEN: LIFSAK. ISSN: 0024-3205. DOCUMENT TYPE: Journal CA Section: 63 (Pharmaceuticals) Short-term kinetics were detd. for nonencapsulated and liposome-encapsulated 59Fe-labeled desferrioxamine [70-51-9] after i.v. administration to mice. A very rapid disappearance of 59Fe-drug was noted from mice plasma receiving multilamellar liposome-encapsulated and noncapsulated drug, but it was much slower in mice receiving unilamellar liposomes. Between 1-24 h after the injection, nonencapsulated 59Fe-desferrioxamine never exceeded 1-5% of the injected dose in liver or <0.7% in spleen, whereas after unilamellar or multilamellar liposomes the liver and spleen uptakes were 30-35% and 1-5%, resp. Excretion of the labeled drug was much slower with liposome encapsulation than without it. Lipsome can effectively deliver desferrioxamine to crit. organs of Fe storage and may be useful in the treatment of Fe-overload diseases.